• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过生物膜的改进递送 VIII:阿司匹林真正前药的设计、合成及体内测试

Improved delivery through biological membranes VIII: Design, synthesis, and in vivo testing of true prodrugs of aspirin.

作者信息

Loftsson T, Kaminski J J, Bodor N

出版信息

J Pharm Sci. 1981 Jul;70(7):743-9. doi: 10.1002/jps.2600700708.

DOI:10.1002/jps.2600700708
PMID:7264918
Abstract

Novel activated ester-type prodrugs of aspirin were designed and synthesized. The methylthiomethyl, methylsulfinymethyl, and methylsulfonylmethyl esters of aspirin (acetylsalicylic acid) were cleaved in vitro in plasma to form aspirin rather than the corresponding salicylates. In vitro studies using dogs indicated that at least one aspirin derivative, methylsulfinylmethyl-2-acetoxybenzoate, is a true aspirin prodrug since aspirin was detected in the blood after prodrug administration.

摘要

设计并合成了新型阿司匹林活化酯型前药。阿司匹林(乙酰水杨酸)的甲硫基甲酯、甲亚磺酰甲酯和甲磺酰甲酯在体外血浆中会裂解形成阿司匹林,而非相应的水杨酸盐。使用犬类进行的体外研究表明,至少有一种阿司匹林衍生物,即甲亚磺酰甲酯 -2- 乙酰氧基苯甲酸酯,是一种真正的阿司匹林前药,因为在前药给药后血液中检测到了阿司匹林。

相似文献

1
Improved delivery through biological membranes VIII: Design, synthesis, and in vivo testing of true prodrugs of aspirin.通过生物膜的改进递送 VIII:阿司匹林真正前药的设计、合成及体内测试
J Pharm Sci. 1981 Jul;70(7):743-9. doi: 10.1002/jps.2600700708.
2
Improved delivery through biological membranes IX: Kinetics and mechanism of hydrolysis of methylsulfinymethyl 2-acetoxybenzoate and related aspirin prodrugs.
J Pharm Sci. 1981 Jul;70(7):750-5. doi: 10.1002/jps.2600700709.
3
Improved delivery through biological membranes XD: Percutaneous absorption and metabolism of methylsulfinylmethyl 2-acetoxybenzoate and related aspirin prodrugs.
J Pharm Sci. 1981 Jul;70(7):756-8. doi: 10.1002/jps.2600700710.
4
Evaluation of glycolamide esters and various other esters of aspirin as true aspirin prodrugs.
J Med Chem. 1989 Mar;32(3):727-34. doi: 10.1021/jm00123a040.
5
Discovery of a "true" aspirin prodrug.一种“真正的”阿司匹林前药的发现。
J Med Chem. 2008 Dec 25;51(24):7991-9. doi: 10.1021/jm801094c.
6
Chemical feasibility studies concerning potential prodrugs of acetylsalicylic acid.关于乙酰水杨酸潜在前体药物的化学可行性研究。
Acta Chem Scand B. 1983;37(4):351-9. doi: 10.3891/acta.chem.scand.37b-0351.
7
Isosorbide-based aspirin prodrugs. II. Hydrolysis kinetics of isosorbide diaspirinate.基于异山梨醇的阿司匹林前药。II. 异山梨醇双阿司匹林酯的水解动力学。
Eur J Pharm Sci. 2002 Sep;16(4-5):297-304. doi: 10.1016/s0928-0987(02)00124-0.
8
Isosorbide-based aspirin prodrugs: integration of nitric oxide releasing groups.基于异山梨醇的阿司匹林前药:一氧化氮释放基团的整合
J Med Chem. 2009 Nov 12;52(21):6588-98. doi: 10.1021/jm900561s.
9
Aspirin prodrugs: synthesis of 2-substituted 2-methyl-4H-1,3-benzodioxin-4-ones and their screening for prodrug potential.阿司匹林前药:2-取代-2-甲基-4H-1,3-苯并二恶英-4-酮的合成及其前药潜力筛选
Acta Chem Scand (Cph). 1990 Oct;44(9):952-6. doi: 10.3891/acta.chem.scand.44-0952.
10
Enzymatic and nonenzymatic in vitro hydrolysis of 2-methyl-2-[2-(methoxy)phenoxy]-4H-1,3-benzodioxin-4-one and 2-methoxyphenyl O-acetylsalicylate.2-甲基-2-[2-(甲氧基)苯氧基]-4H-1,3-苯并二恶英-4-酮和2-甲氧基苯基O-乙酰水杨酸酯的酶促和非酶促体外水解
J Pharm Sci. 1991 Jun;80(6):545-7. doi: 10.1002/jps.2600800609.

引用本文的文献

1
Autocatalytic methylthiomethylation of carboxylic acid/phenol involving the formation of DMSO enolate: convenient synthesis of methylthiomethyl ester/ether.涉及二甲基亚砜烯醇盐形成的羧酸/苯酚的自催化甲硫基甲基化反应:甲硫基甲酯/醚的简便合成方法
RSC Adv. 2022 Nov 18;12(51):33156-33159. doi: 10.1039/d2ra06618a. eCollection 2022 Nov 15.
2
Skin structure and metabolism: relevance to the design of cutaneous therapeutics.皮肤结构与代谢:与皮肤治疗药物设计的相关性。
Pharm Res. 1984 Jul;1(4):148-53. doi: 10.1023/A:1016340423079.
3
Soft drugs. XX. Design, synthesis, and evaluation of ultra-short acting beta-blockers.
软性毒品。XX。超短效β受体阻滞剂的设计、合成与评价。
Pharm Res. 1995 Mar;12(3):329-36. doi: 10.1023/a:1016283930696.